cryptosporidium
parvum
one
main
caus
diarrhea
neonat
calv
result
signific
morbid
econom
loss
produc
worldwid
previous
demonstr
efficaci
new
class
antimicrobi
antibodi
fusion
neonat
mous
model
c
parvum
infect
extend
efficaci
test
product
experiment
infect
calv
princip
target
speci
neonat
calv
challeng
c
parvum
oocyst
concomitantli
treat
antibodybiocid
fusion
cours
four
day
result
reduc
sever
diseas
compar
control
anim
overal
clinic
health
paramet
show
signific
improv
treat
anim
oocyst
shed
reduc
treat
compar
control
anim
control
oocyst
shed
prerequisit
break
cycl
reinfect
dairi
farm
antibodybiocid
fusion
product
thu
potenti
reduc
impact
infect
individu
anim
herd
cryptosporidi
infect
one
common
caus
diarrhea
human
livestock
worldwid
fayer
fayer
et
al
tzipori
widmer
wyatt
et
al
preval
speci
produc
diseas
cattl
cryptosporidium
parvum
caus
extens
econom
loss
young
calv
although
case
remain
subclin
wyatt
et
al
c
parvum
primari
contributor
neonat
diarrhea
complex
along
rotaviru
coronaviru
escherichia
coli
one
import
zoonot
agent
diarrhea
calv
age
one
month
naciri
et
al
sever
affect
anim
may
die
often
selflimit
diarrhea
result
morbid
increas
labor
veterinari
cost
degraaf
et
al
infect
anim
usual
shed
larg
number
infect
oocyst
fece
nydam
et
al
dairi
calv
preval
shed
report
highest
among
anim
day
age
prepat
period
day
fayer
absenc
effect
approv
drug
usa
control
cryptosporidiosi
calv
reli
mainli
hygien
measur
good
manag
wyatt
et
al
varieti
therapeut
prophylact
metaphylact
pharmaceut
test
efficaci
c
parvum
human
anim
vari
result
silverla
et
al
stockdal
et
al
zhu
halofuginon
paromomycin
test
veterinari
use
accord
recent
review
metaanalysi
studi
investig
multipl
field
trial
calv
benefit
halofuginon
treatment
silverla
et
al
halofuginon
lactat
halocur
intervet
see
front
matter
elsevi
bv
right
reserv
approv
use
sever
european
countri
paromomycin
sulphat
gabbrovet
ceva
animal
avail
inject
bacteri
infect
countri
piglet
calv
poultri
vaccin
made
kill
c
parvum
oocyst
goff
repetit
passag
precoci
strain
c
parvum
fayer
test
abil
protect
calv
diarrhea
limit
oocyst
shed
vaccin
dayold
calv
use
gamma
irradi
oocyst
reduc
oocyst
shed
diarrhea
challeng
c
parvum
day
jenkin
et
al
howev
field
trial
kill
vaccin
alway
convincingli
shown
protect
goff
increas
awar
need
develop
new
effici
safer
product
control
cryptosporidiosi
livestock
stockdal
et
al
passiv
immun
cryptosporidiosi
investig
use
variou
strategi
found
effect
reduc
infect
burton
et
al
imboden
et
al
perryman
et
al
schaefer
et
al
formul
monoclon
antibodi
mab
provid
signific
addit
prophylact
efficaci
individu
mab
neonat
icr
mice
schaefer
et
al
studi
use
adult
scid
mous
model
evalu
therapeut
effect
mab
highli
signific
efficaci
reduc
elimin
persist
c
parvum
infect
demonstr
rigg
et
al
studi
evalu
prophylact
efficaci
mab
oocyst
challeng
conduct
calv
result
demonstr
signific
reduct
sever
diarrhea
oocyst
shed
rigg
et
al
studi
demonstr
efficaci
antibodybas
treatment
cryptosporidiosi
effect
treatment
dose
bioreactorproduc
mab
use
cost
prohibit
develop
econom
feasibl
veterinari
product
attempt
improv
treatment
efficaci
mab
design
molecul
consist
mab
arm
membranedisrupt
peptid
biocid
mammalian
innat
immun
arsen
imboden
et
al
select
mab
base
work
schaefer
et
al
describ
signific
sporozoit
neutral
vitro
reduct
infect
neonat
mice
panel
mab
produc
surfaceexpos
antigen
c
parvum
sporozoit
among
other
mab
produc
antigen
complex
c
parvum
chosen
develop
antibodybiocid
fusion
schaefer
et
al
done
genet
link
code
sequenc
mab
heavi
chain
code
sequenc
human
cathelicidinderiv
antimicrobi
peptid
result
construct
express
highli
effici
retrovectorbas
mammalian
cell
cultur
system
test
novel
immunotherapeut
neonat
icr
mous
infect
asymptomat
model
reveal
achiev
sporozoit
neutral
fold
lower
dose
c
parvumspecif
neutral
mab
potent
neutral
antibodi
identifi
date
imboden
et
al
dose
respons
mous
trial
demonstr
efficaci
dosag
low
mgkgd
given
day
imboden
et
al
studi
allow
establish
effect
dose
oral
administ
antibodybiocid
fusion
rodent
present
studi
assess
efficaci
experiment
c
parvum
infect
calf
model
sever
clinic
parasitolog
paramet
use
compar
anim
treat
antibodybiocid
fusion
control
iowa
c
parvum
isol
hein
et
al
sourc
oocyst
experi
maintain
sinc
propag
newborn
cryptosporidiumfre
holstein
bull
calv
rigg
et
al
rigg
perryman
oocyst
isol
calf
fece
sucros
densiti
gradient
centrifug
store
kcr
c
arrowood
donaldson
rigg
perryman
calf
mous
challeng
studi
oocyst
use
within
day
isol
disinfect
peracet
acid
immedi
prior
administr
rigg
et
al
oocyst
excyst
determin
immedi
prior
administr
obtain
isol
sporozoit
alway
exceed
genet
construct
use
produc
recombin
product
use
studi
assembl
describ
earlier
imboden
et
al
briefli
total
rna
hybridoma
cell
revers
transcrib
subject
degener
primer
pcr
use
immunoglobulin
clone
kit
accord
manufactur
instruct
novagen
emd
chemic
gibbstown
nj
isol
variabl
region
heavi
light
chain
gene
variabl
region
obtain
link
murin
heavi
light
chain
constant
region
respect
heavi
chain
constant
region
previous
engin
imboden
et
al
contain
human
sequenc
attach
ctermin
end
fulli
assembl
heavi
light
chain
construct
transduc
cho
chines
hamster
ovari
cell
use
pantrop
moloney
murin
leukemia
virusbas
retrovir
express
vector
system
clontech
mountain
view
ca
due
high
effici
transduct
cell
pool
secret
antibodybiocid
fusion
subject
standard
limit
dilut
clone
isol
clonal
cell
line
pilot
scale
product
l
benchtop
fermentor
wave
bioreactor
tm
system
ge
piscataway
nj
studi
separ
l
batch
cho
cell
control
cho
cell
contain
transgen
grown
four
cohort
calv
describ
product
batch
treat
process
ident
upon
harvest
cultur
via
centrifug
supernat
subject
cross
flow
filtrat
use
kda
ultrafiltr
cartridg
remov
lower
molecular
weight
rang
contamin
concentr
product
dialys
sampl
salin
follow
cross
flow
filtrat
product
quantifi
elisa
detect
heavi
light
chain
blindcod
singledos
aliquot
control
cho
cell
supernat
control
substanc
prepar
ship
frozen
univers
arizona
aliquot
product
batch
retain
test
separ
neonat
mous
efficaci
trial
confirm
product
consist
data
shown
statist
differ
efficaci
observ
four
batch
data
shown
batch
effect
reduc
infect
neonat
mous
model
consist
publish
data
imboden
et
al
total
sixteen
newborn
holstein
bull
calv
obtain
close
herd
product
unit
approxim
dairi
cow
cohort
calv
assembl
agematch
cohort
calv
cow
calv
within
maximum
h
period
select
calv
manual
assist
calv
deliv
onto
plastic
sheet
prevent
contamin
enteropathogen
might
otherwis
confound
interpret
result
place
individu
disinfect
transport
crate
contain
autoclav
straw
upon
arriv
univers
arizona
central
anim
facil
unit
calf
randomli
assign
group
use
microsoft
excel
random
number
gener
tool
weigh
place
elev
calf
stall
wenk
manufactur
pender
ne
equip
urin
fecal
collect
pan
calf
weight
kg
singl
ear
tag
appli
serv
calf
identifi
number
studi
commerci
colostrum
replac
bovin
igg
colostrum
replac
land
olak
shoreview
mn
singl
product
lot
calv
studi
administ
within
h
birth
per
label
instruct
adequaci
passiv
transfer
colostr
igg
determin
use
commerci
avail
sodium
sulfit
precipit
test
serum
calf
collect
h
age
bova
bovin
fpt
test
kit
vmrd
inc
pullman
wa
calv
reach
serum
level
immunoglobulin
mgml
defin
adequ
transfer
bose
vitamin
ese
supplement
kg
merck
whitehous
station
nj
inject
subcutan
calf
within
h
birth
begin
h
age
calv
maintain
reconstitut
milk
replac
nutrena
snowflak
calf
milk
iiutiliz
milk
replac
medic
cargil
anim
nutrit
minneapoli
mn
twice
daili
bodi
weight
arriv
day
thereaft
termin
experi
day
post
infect
dpi
end
acclim
period
h
overal
clinic
examin
perform
determin
health
statu
prior
admit
anim
studi
calv
observ
fever
c
diarrhea
respiratori
distress
inabl
rise
inappet
exclus
need
base
health
paramet
individu
fecal
sampl
collect
calf
determin
presenc
known
viral
bacteri
enteropathogen
agent
rotaviru
coronaviru
e
coli
andor
salmonella
h
post
oocyst
challeng
dpi
negativestain
electron
microscopi
use
direct
examin
fece
identifi
rotaviru
coronaviru
particl
aerob
cultur
perform
fece
detect
presenc
aerob
bacteri
pathogen
sheep
blood
agar
agar
hardi
diagnost
santa
maria
ca
use
routin
aerob
cultur
wherea
tetrathion
broth
agar
hardi
use
salmonella
cultur
enter
bacteria
identifi
routin
biochem
test
anon
presenc
antigen
e
coli
isol
evalu
e
coli
antigen
latex
agglutin
test
kit
pilitest
vwrd
inc
pullman
wa
sampl
found
neg
pathogen
calv
examin
daili
veterinarian
cohort
consist
two
group
two
anim
one
group
receiv
group
receiv
control
substanc
personnel
involv
calf
handl
unawar
treatment
ident
singleblind
studi
trial
total
cohort
anim
recruit
two
treatment
group
test
substancetr
ii
control
substancetr
anim
anim
belong
treatment
group
statist
analyz
one
group
ie
data
treatment
group
averag
across
cohort
test
substancetr
control
substancetr
anim
hous
separ
room
prior
oocyst
challeng
h
age
individu
fecal
sampl
collect
examin
c
parvum
oocyst
acidfast
stain
confirm
neg
smith
day
oocyst
inocul
defin
cohort
dpi
calv
challeng
h
age
calf
fed
ml
milk
replac
nippl
bottl
close
gastric
groov
immedi
thereaft
ml
syring
contain
c
parvum
oocyst
ml
milk
replac
administ
oral
follow
ml
prealiquot
dose
blindcod
control
substanc
mix
milk
replac
fed
nippl
bottl
two
dose
regimen
use
cohort
treat
mg
mgkgd
concomit
challeng
h
h
h
h
h
post
infect
total
treatment
ii
cohort
treat
mg
mgkgd
concomit
challeng
h
h
h
h
h
h
h
h
post
infect
total
treatment
equal
volum
control
substanc
consist
cho
cell
supernat
process
ident
given
control
anim
time
interv
treatment
calf
fed
ml
milk
replac
nippl
bottl
close
gastric
groov
follow
immedi
ml
contain
prealiquot
dose
control
substanc
appropri
amount
milk
replac
bodi
weight
total
per
day
potabl
water
l
per
bucket
made
avail
ad
libitum
oral
electrolyt
resorb
pfizer
avail
bucket
calf
onset
diarrhea
evalu
anim
includ
fecal
parasitolog
paramet
well
clinic
observ
gener
health
food
intak
paramet
fecal
collect
pan
posit
beneath
rear
stall
ensur
accur
collect
fece
subsequ
analys
contamin
fecal
pan
urin
prevent
attach
dispos
h
urin
absorpt
pad
cover
preputi
region
attach
fullwidth
angl
plastic
shield
undersid
stall
floor
divert
urin
leakag
separ
collect
pan
shield
place
urin
divert
fece
allow
pass
fecal
collect
pan
fecal
volum
ml
measur
fecal
consist
evalu
twice
daili
calf
fece
daili
collect
thoroughli
mix
industri
blender
hamilton
beach
southern
pine
nc
ensur
sampl
uniform
ml
repres
sampl
obtain
kept
c
oocyst
quantif
oocyst
quantifi
ifa
use
oocystspecif
mab
previous
describ
rigg
et
al
clinic
paramet
assess
twice
daili
assign
score
individu
score
record
fecal
consist
form
loos
diarrheic
diarrheic
sever
diarrheic
wateri
profus
willing
rise
eager
rise
alreadi
will
rise
need
encourag
reluct
rise
abl
assist
unwil
rise
requir
lift
stanc
stabl
normal
somewhat
unstabl
clearli
unstabl
lose
balanc
sway
unabl
stand
appetit
raven
aggress
normal
decreas
coax
suckl
anorect
suckl
attitud
bright
alert
respons
somewhat
depress
dull
clearli
depress
minim
respons
hydrat
statu
normal
dehydr
evid
dehydr
test
skin
tent
test
care
provid
grasp
skin
abdomen
rib
cage
two
finger
tent
skin
held
second
releas
skin
normal
turgor
snap
rapidli
back
normal
posit
skin
decreas
turgor
remain
elev
return
slowli
normal
posit
indic
dehydr
intak
ml
milk
replac
water
electrolyt
record
twice
daili
bodyweight
record
start
termin
trial
use
comput
averag
bodyweight
gain
statist
design
consist
random
complet
block
design
four
anim
per
cohort
block
two
treatment
measur
physiolog
clinic
paramet
specifi
averag
score
health
paramet
calcul
averag
score
among
anim
treatment
day
best
possibl
score
healthi
anim
accordingli
worst
score
sick
anim
statist
analysi
carri
use
model
platform
jmp
version
sa
institut
cari
nc
full
factori
regress
model
use
follow
effect
interact
model
cohort
treatment
cohort
treatment
cohort
day
treatment
day
cohort
treatment
day
regress
analysi
time
day
treat
continu
fix
effect
variabl
day
model
fix
effect
use
knot
spline
describ
stone
koo
regress
model
time
fix
effect
chosen
rather
repeat
measur
analysi
natur
biolog
respons
nonrandom
timedepend
respons
depend
time
measur
rel
parasit
challeng
regard
studi
akin
pharmacokineticpharmacodynam
studi
spline
function
use
model
use
knot
spline
make
possibl
direct
area
curv
measur
fit
biolog
pattern
use
knot
spline
similar
use
polynomi
term
model
close
fit
experiment
data
detail
exampl
output
model
platform
oocyst
shed
data
found
supplement
fig
due
improv
product
techniqu
product
becam
avail
trial
cohort
finish
con
trol
p
fig
daili
clinic
score
clinic
paramet
score
describ
method
score
anim
cohort
treatment
group
use
calcul
mean
daili
health
score
error
bar
repres
daili
standard
error
anim
treatment
group
calv
statist
analysi
daili
mean
treat
control
group
signific
differ
done
full
factori
regress
model
describ
method
pvalu
indic
statist
significantli
better
health
score
anim
compar
controltr
anim
observ
period
day
despit
fact
trial
alreadi
start
decid
increas
dose
mg
mg
treatment
treatment
detail
see
section
subsequ
cohort
termin
trial
statist
analysi
compar
two
treatment
regimen
perform
signific
differ
observ
data
shown
therefor
decid
consolid
data
cohort
statist
analysi
two
control
calv
die
one
cohort
day
pi
due
volvulu
small
intestin
one
cohort
day
pi
due
acut
sever
bacteri
periton
secondari
omphalophleb
measur
overal
health
defin
clinic
paramet
assess
daili
use
score
system
describ
method
anim
significantli
better
mean
overal
health
score
compar
control
anim
fig
p
differ
pronounc
day
pi
period
clinic
sign
cryptosporidiosi
typic
greatest
sever
treat
anim
score
versu
control
anim
score
fig
calcul
across
durat
trial
individu
paramet
score
significantli
differ
control
treat
calv
tabl
data
indic
treatment
reliev
diseas
sign
cryptosporidiosi
one
import
paramet
measur
posit
treatment
effect
cryptosporidiosi
reduct
fecal
oocyst
shed
experiment
protocol
design
accur
measur
total
daili
oocyst
output
multipli
oocyst
count
deriv
homogen
daili
sampl
total
daili
fecal
volum
mean
daili
oocyst
output
anim
significantli
lower
period
day
post
infect
mean
daili
oocyst
output
controltr
anim
p
reduct
greatest
peak
period
shed
day
pi
fig
cumul
oocyst
shed
entir
trial
show
reduct
calv
compar
control
substancetr
calv
fig
c
parvum
infect
one
common
caus
diarrhea
livestock
worldwid
recognit
econom
impact
grown
clear
need
develop
effect
parasitespecif
safer
product
control
c
parvum
infect
antibodybiocid
fusion
novel
compound
previous
shown
efficaci
c
parvum
infect
neonat
mous
model
imboden
et
al
develop
veterinari
human
use
fusion
deriv
specif
variabl
region
monoclon
antibodi
direct
complex
c
parvum
sporozoit
surfac
schaefer
et
al
parasiticid
function
human
cathelicidin
deriv
peptid
antimicrobi
peptid
found
neutral
effect
sporozoit
vitro
manuscript
submit
clinic
pilot
studi
test
efficaci
calv
experiment
infect
c
parvum
oocyst
compar
sever
clinic
parasitolog
paramet
control
substancetr
anim
treatment
efficaci
demonstr
improv
health
paramet
reduc
oocyst
shed
cryptosporidiuminfect
calv
reduct
fecal
output
treat
anim
data
shown
detect
epidemiolog
perspect
reduct
tabl
clinic
observ
score
analyz
full
factori
regress
model
accord
experiment
model
describ
method
treatment
compar
anim
cohort
controltr
anim
cohort
regard
health
paramet
cohort
compar
differ
cohort
contain
controltr
anim
regard
health
paramet
control
treatment
compar
cohort
regard
treatment
health
paramet
day
knot
indic
knot
spline
transform
use
accommod
timevari
respons
regard
treatment
day
health
paramet
data
collect
day
day
conclus
experi
df
degre
freedom
oocyst
shed
import
factor
help
reduc
parasit
pool
environ
awar
fact
overal
reduct
oocyst
shed
might
suffic
control
spread
diseas
might
make
signific
contribut
comprehens
cryptosporidium
control
program
given
farm
reduct
parasit
pool
would
result
reduc
dairi
herd
infect
well
reduc
likelihood
human
exposur
direct
contact
farm
via
drink
recreat
water
suppli
contamin
studi
conduct
design
demonstr
efficaci
novel
biotherapeut
larg
anim
model
cryptosporidiosi
use
least
possibl
number
anim
highest
technic
feasibl
oral
treatment
dose
despit
fact
two
control
anim
lost
prematur
due
unrel
complic
studi
design
strong
enough
demonstr
signific
oocyst
shed
overal
health
paramet
studi
provid
proof
concept
novel
biotherapeut
clinic
model
cryptosporidiosi
treatment
regimen
dose
chosen
larg
base
previou
efficaci
data
neonat
mous
model
imboden
et
al
base
assumpt
initi
elev
dose
first
h
challeng
import
achiev
therapeut
effect
whether
subsequ
regimen
consist
interv
dose
posit
neg
impact
natur
asynchron
life
cycl
cryptosporidium
exposur
extracellular
stage
infect
known
howev
success
proof
concept
studi
serv
start
point
develop
antibodybiocid
fusion
efficaci
trial
effort
test
treatment
regimen
adapt
field
applic
dairi
farm
focu
test
less
frequent
treatment
schedul
lower
treatment
dose
gener
fieldlik
condit
futur
trial
also
includ
anim
lower
multipl
challeng
dose
lower
challeng
dose
use
present
studi
shown
other
induc
diarrhea
larg
number
calv
infect
rate
lower
oocyst
number
shed
moor
et
al
perryman
et
al
see
dosedepend
efficaci
product
mice
imboden
et
al
like
lower
oocyst
challeng
number
result
lower
number
shed
oocyst
would
allow
lower
treatment
dose
antibodi
fusion
product
achiev
efficaci
